Arvinas, Inc. (NASDAQ:ARVN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Arvinas, Inc. (NASDAQ:ARVN) have received an average rating of “Moderate Buy” from the fourteen research firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and thirteen have issued a buy rating on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $60.00.

ARVN has been the subject of several recent research reports. HC Wainwright reaffirmed a “buy” rating and issued a $87.00 price target on shares of Arvinas in a report on Thursday, October 31st. Oppenheimer cut their target price on Arvinas from $50.00 to $40.00 and set an “outperform” rating for the company in a research note on Thursday, October 31st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arvinas in a research note on Monday, September 9th. Wedbush restated an “outperform” rating and issued a $57.00 price objective on shares of Arvinas in a research note on Tuesday, July 30th. Finally, Barclays reduced their price objective on shares of Arvinas from $60.00 to $48.00 and set an “overweight” rating for the company in a report on Wednesday, July 31st.

Hedge Funds Weigh In On Arvinas

A number of institutional investors and hedge funds have recently bought and sold shares of ARVN. Vanguard Group Inc. lifted its position in Arvinas by 29.9% during the 1st quarter. Vanguard Group Inc. now owns 6,299,556 shares of the company’s stock worth $260,046,000 after buying an additional 1,448,166 shares in the last quarter. Swiss National Bank grew its stake in shares of Arvinas by 27.5% during the first quarter. Swiss National Bank now owns 114,100 shares of the company’s stock valued at $4,710,000 after purchasing an additional 24,600 shares during the last quarter. SG Americas Securities LLC increased its holdings in shares of Arvinas by 137.2% in the second quarter. SG Americas Securities LLC now owns 86,096 shares of the company’s stock valued at $2,292,000 after purchasing an additional 49,799 shares in the last quarter. Candriam S.C.A. increased its holdings in shares of Arvinas by 32.0% in the second quarter. Candriam S.C.A. now owns 610,458 shares of the company’s stock valued at $16,250,000 after purchasing an additional 147,904 shares in the last quarter. Finally, Magnetar Financial LLC raised its position in Arvinas by 112.7% in the 2nd quarter. Magnetar Financial LLC now owns 41,992 shares of the company’s stock worth $1,118,000 after purchasing an additional 22,245 shares during the last quarter. Institutional investors and hedge funds own 95.19% of the company’s stock.

Arvinas Trading Down 3.7 %

Shares of Arvinas stock opened at $25.34 on Thursday. Arvinas has a 1 year low of $17.12 and a 1 year high of $53.08. The company’s fifty day simple moving average is $25.82 and its 200-day simple moving average is $27.39. The company has a market cap of $1.74 billion, a price-to-earnings ratio of -5.43 and a beta of 1.96.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings data on Wednesday, October 30th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.20. The company had revenue of $102.40 million for the quarter, compared to the consensus estimate of $60.56 million. The business’s revenue for the quarter was up 196.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.18) EPS. As a group, research analysts forecast that Arvinas will post -3.32 earnings per share for the current fiscal year.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.